Cargando…

Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance

Recent insight in the genomic landscape of newly diagnosed multiple myeloma (NDMM) and its precursor conditions, monoclonal gammopathy of uncertain significance (MGUS), and smoldering myeloma have allowed the identification of patients with precursor conditions with a high risk of progression. These...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mejia Saldarriaga, Mateo, Darwiche, Walaa, Jayabalan, David, Monge, Jorge, Rosenbaum, Cara, Pearse, Roger N., Niesvizky, Ruben, Bustoros, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646612/ https://www.ncbi.nlm.nih.gov/pubmed/36387095 http://dx.doi.org/10.3389/fonc.2022.1020011

Ejemplares similares

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Reported in ALL
por: Mejia Saldarriaga, Mateo, et al.
Publicado: (2019)

Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics
por: Alonso, Rafael, et al.
Publicado: (2022)

Bone marrow niche in multiple myeloma and its precursor states
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2019)

The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges
por: Lazaris, Vasileios, et al.
Publicado: (2021)

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2022)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
por: Leblay, Noémie, et al.
Publicado: (2020)

Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma
por: Wei, Yujun, et al.
Publicado: (2022)

Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets
por: Petrusca, Daniela N., et al.
Publicado: (2022)

Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
por: Keller, Alana L., et al.
Publicado: (2022)

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
por: Perez de Acha, Olivia, et al.
Publicado: (2023)

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
por: Yang, Ying, et al.
Publicado: (2021)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Multiple Myeloma Mimicking a Small Vessel Vasculitis Presentation
por: Mejía-Zuluaga, Mateo, et al.
Publicado: (2020)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Current Role of Radiation Therapy for Multiple Myeloma
por: Talamo, Giampaolo, et al.
Publicado: (2015)

An Uncommon Cause of Acute Encephalopathy in Multiple Myeloma
por: Al Zeyoudi, Jawaher, et al.
Publicado: (2021)

PET/CT in Multiple Myeloma: Beyond FDG
por: Matteucci, Federica, et al.
Publicado: (2021)

Editorial: T-cell directed therapies in multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2023)

PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population
por: Wang, Yajun, et al.
Publicado: (2022)

Integrated Transcriptomic Analysis Reveals a Distinctive Role of YAP1 in Extramedullary Invasion and Therapeutic Sensitivity of Multiple Myeloma
por: Zheng, Bo, et al.
Publicado: (2022)

Multiple myeloma and physical activity: a scoping review
por: Smith, Lee, et al.
Publicado: (2015)

Multiple myeloma with testicular involvement: A case report
por: Yamashita, Kaori, et al.
Publicado: (2019)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
por: Bobin, Arthur, et al.
Publicado: (2020)

Testicular plasmocytoma as an unsual late relapse of multiple myeloma
por: Karray, Omar, et al.
Publicado: (2020)

Tumor Microenvironment Proteomics: Lessons From Multiple Myeloma
por: Fernando, Rodrigo Carlini, et al.
Publicado: (2021)

Immunoglobulin D Multiple Myeloma: A Rare Variant
por: MacDougall, Kira N, et al.
Publicado: (2022)

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
por: Romano, Alessandra, et al.
Publicado: (2021)

Infiltration of the spinal cord and peripheral nerves in multiple myeloma
por: Su, Xiaoyun, et al.
Publicado: (2022)

Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function
por: Zhou, Liang, et al.
Publicado: (2020)

Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
por: Heinemann, Luca, et al.
Publicado: (2022)

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine
por: Mark, Daniel, et al.
Publicado: (2019)

Calvarial Plasmacytoma Mimicking Meningioma as the Initial Presentation of Multiple Myeloma
por: Morgenstern, Peter, et al.
Publicado: (2017)

Multiple Myeloma Relapse as Intracranial Plasmacytoma: A Rare Presentation
por: Prakash, Amulya, et al.
Publicado: (2020)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2020)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mb2nlg131cl2iplbvo7mj4nv3j